BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10232368)

  • 1. Cell biology of CML cells.
    Gordon MY; Dazzi F; Marley SB; Lewis JL; Nguyen D; Grand FH; Davidson RJ; Goldman JM
    Leukemia; 1999 Apr; 13 Suppl 1():S65-71. PubMed ID: 10232368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell biology of CML--a model linking the chronic and terminal phases.
    Gordon MY
    Leuk Lymphoma; 1993; 11 Suppl 1():93-100. PubMed ID: 8251924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
    Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
    J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myelogenous leukemia: mechanisms underlying disease progression.
    Shet AS; Jahagirdar BN; Verfaillie CM
    Leukemia; 2002 Aug; 16(8):1402-11. PubMed ID: 12145676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
    Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloid leukemia stem cells.
    Jamieson CH
    Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of Bcr-Abl protein tyrosine kinase on maturation and proliferation of primitive haematopoietic cells.
    Buckle AM; Mottram R; Pierce A; Lucas GS; Russell N; Miyan JA; Whetton AD
    Mol Med; 2000 Oct; 6(10):892-902. PubMed ID: 11126203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New understanding of the pathogenesis of CML: a prototype of early neoplasia.
    Clarkson BD; Strife A; Wisniewski D; Lambek C; Carpino N
    Leukemia; 1997 Sep; 11(9):1404-28. PubMed ID: 9305592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment.
    Clarkson B; Strife A
    Leukemia; 1993 Nov; 7(11):1683-721. PubMed ID: 8231240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biology of normal and neoplastic stem cells in CML.
    Eaves C; Udomsakdi C; Cashman J; Barnett M; Eaves A
    Leuk Lymphoma; 1993; 11 Suppl 1():245-53. PubMed ID: 8251904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia.
    Krämer A; Löffler H; Bergmann J; Hochhaus A; Hehlmann R
    Leukemia; 2001 Jan; 15(1):62-8. PubMed ID: 11243401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.